Trials / Terminated
TerminatedNCT01397734
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this research study, the investigators are looking to see whether the combination of arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic myelogenous leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arsenic trioxide | 0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle. |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2018-08-06
- Completion
- 2018-08-06
- First posted
- 2011-07-20
- Last updated
- 2018-09-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01397734. Inclusion in this directory is not an endorsement.